The implant offers larger size options for breast reconstruction after mastectomy, addressing the needs of the 1 in 7 women previously underserved by size limitations.
Johnson & Johnson MedTech announced the US launch of Mentor MemoryGel Enhance Breast Implants, aiming to fill a gap in comprehensive breast cancer care for women who have undergone a mastectomy.
Designed for primary or revision reconstruction following a mastectomy, the US Food and Drug Administration (FDA)-approved Mentor MemoryGel Enhance Breast Implants are developed specifically for women with larger breasts, offering sizes from 930 cc to 1445 cc and giving surgeons the ability to deliver more personalized outcomes without compromising aesthetic results.
The breast implants address the needs of approximately 15% of post-mastectomy patients who previously lacked access to appropriately sized implants for reconstruction.
“Johnson & Johnson MedTech is delivering on our promise to make breast reconstruction more inclusive, supportive, and empowering for every woman,” says Alenka Brzulja, worldwide president of aesthetics and reconstruction at Johnson & Johnson MedTech, in a release. “Too many women have been left without options that helped them achieve their desired outcomes. The availability of MemoryGel Enhance Implants brings us closer to addressing this gap—because every woman deserves access to reconstruction options that reflect her body and her goals.”
Offering Choice for Patients Post-mastectomy
With breast cancer rates continuing to rise across the US, more than 246,000 women undergo a mastectomy each year as part of breast cancer treatment or prevention. Breast reconstruction offers these women the option to rebuild their breasts after surgery using implants, restoring both form and volume.
Without a size-appropriate implant, patients may face symmetry issues, suboptimal aesthetic outcomes, or the need for additional surgeries to achieve their desired results. Until now, the largest implant available was 800 cc, making it difficult for patients with larger body frames or extensive tissue removal to achieve proportional results and leading to lower reconstruction rates.
MemoryGel Enhance Implants offer the same proprietary gel formulation, softness, and shape retention as the existing Mentor portfolio and are now available in larger sizes with an expanded range of base widths, projections, and volumes to better meet the reconstruction needs of more patients. The Mentor Enhance product family includes MemoryGel Enhance Implants, CPX4 Plus Enhance Breast Tissue Expanders, and MemoryGel Enhance Breast Implant Sizers, designed to work together to support a complete reconstruction experience.
“Despite being a standard part of post-mastectomy care, reconstruction options have not kept pace with the diverse needs of today’s patient population,” says Mark Migliori, MD, FACS, board-certified plastic surgeon in Edina, Minnesota, who performed the first procedure with the new implant, in a release. “For patients who require a larger-volume implant than what was previously available, they now have an option that helps them to become whole again.”
Mentor MemoryGel Enhance Breast Implants were approved by the US FDA for primary and revision reconstruction in November 2024. Three-year data from the Athena Study, the largest multicenter, prospective 10-year clinical trial of breast implants for reconstruction, demonstrated the safety and efficacy of larger implants, including 96% overall patient satisfaction, low complication rates, and significant improvements in physical, psychosocial, and sexual well-being.
Photo caption: MemoryGel Enhance
Photo credit: Johnson & Johnson
